Hecla Mining walks into its Q1 2026 earnings call with the stock bruised, analysts trimming numbers, and options traders the most defensively positioned they've been all year.
The price tells the story plainly. HL closed at $17.05 on Tuesday, down 11% over the past month and 4.4% on the week alone. The stock has shed nearly a third of its value from the February high of roughly $25. Tuesday's single-session decline of 3% came the day before the scheduled earnings release, a sign the market was repositioning rather than holding steady into the print.
Analyst moves this week crystallised the cautious mood. HC Wainwright's Heiko Ihle cut his price target from $36.50 to $26.75 today — a 27% reduction — while keeping his Buy rating. That's a notable markdown from an analyst who was among the most bullish voices on the stock just four months ago. Canaccord Genuity moved in the opposite direction on April 29, upgrading from Hold to Buy with a $24 target. The net result is a Street that is bifurcated: some see the pullback as an entry point, others are marking down their upside assumptions. The consensus mean target sits at $24.83, still a substantial premium to where the stock is trading, though targets have been moving sharply enough to treat that figure with caution. The only historical earnings reaction in the data shows the stock jumped 7.3% the day after the February print and extended to a 9.7% gain over the following week — worth noting context as the next release approaches.
Options positioning has turned the most defensive it has been in a year. The put/call ratio reached 0.54 on Tuesday — the highest 52-week reading — running above its 20-day average of 0.50 by more than a standard deviation. The move is consistent with investors buying downside protection ahead of the results rather than speculating on an upside surprise. The EPS momentum factor score ranks in just the 11th percentile on a 30-day basis, and EPS surprise is in the 14th percentile, meaning the stock has not been a consistent outperformer on estimates.
Short interest tells a less confrontational story. At 4.86% of the free float, bearish positioning is meaningful but not extreme. It pulled back from around 5% in mid-April to its current level, suggesting some shorts covered into the earlier decline. The month-on-month rise of about 8% in borrowed shares shows a gradual rebuild, but borrowing costs remain minimal at 0.48% — and availability in the lending pool is loose, well above the levels that would signal any squeeze risk. The ORTEX short score of 36.9 is middling, and the utilization rank sits at the 50th percentile. Nothing in the lending market points to forced covering.
Institutional ownership is dense at the top. BlackRock holds 13% of shares, Vanguard nearly 10%, and Van Eck — a natural holder given their metals ETF franchise — another 5.5%. All three added modestly in the most recent filing period. Insider activity from early March saw the CFO, COO, and general counsel sell small amounts at $24.63 — shares now trading well below that price — though those transactions were routine award-related disposals and carry low significance scores.
The EV/EBITDA multiple has compressed roughly 10% over 30 days to 11.1x, moving with the stock rather than against it. Peer silver miners fared no better this week: CDE fell 4% on the week and PAAS dropped 3.8%. EDR was the weakest of the group, down 7.5%. The sector-wide pressure means HL's decline is not idiosyncratic — but the stock has underperformed even that weak peer backdrop over the past month, suggesting company-specific caution is also at work.
The earnings release now becomes the focal point: the question is whether Q1 production and free cash flow data — particularly from the Greens Creek segment — can stabilise sentiment after a steep de-rating, or whether the target cuts we've seen today are the beginning of a wider Street reset.
See the live data behind this article on ORTEX.
Open HL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
